Fiche publication
Date publication
octobre 2023
Journal
JAMA network open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HOTTON Judicaël
Tous les auteurs :
Gougis P, Grandal B, Jochum F, Bihan K, Coussy F, Barraud S, Asselain B, Dumas E, Sebbag C, Hotton J, Spaggiari E, Pierga JY, Savarino R, Laas E, Spano JP, Reyal F, Hamy AS
Lien Pubmed
Résumé
Targeted therapies directed against ERBB2 are the cornerstone of medical treatment for ERBB2-positive breast cancers but are contraindicated during pregnancy.
Mots clés
Infant, Newborn, Female, Pregnancy, Humans, Adult, Lapatinib, Case-Control Studies, Trastuzumab, adverse effects, Ado-Trastuzumab Emtansine, Breast Neoplasms, drug therapy, Antineoplastic Agents, adverse effects, Receptor, ErbB-2
Référence
JAMA Netw Open. 2023 10 2;6(10):e2339934
